Skip to main content

Advertisement

SpringerLink
Log in

Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes

  • Pharmacologic Treatment of Type 2 Diabetes and Obesity (A Vella, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Type 2 diabetes now affects more than 1 in 10 US adults and is a leading cause of morbidity, mortality, and healthcare expense. There are increasing numbers of available pharmacotherapies, with established agents as well as newer drugs developed from hormones in the incretin pathway, among others. New data are accumulating continuously with respect to potential benefits of both long-standing and new agents, as well as risks identified through post-marketing surveillance. Here we review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. 2011. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.

  2. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25.

    Article  PubMed  Google Scholar 

  3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.

    Article  PubMed  CAS  Google Scholar 

  4. Food and Drug Administration: FDA significantly restricts access to the diabetes drug Avandia. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm. Accessed January 3, 2013.

  5. • Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602–13. This is a comprehensive and methodical review of comparative effectiveness trials. It is an update from a previous review, with this iteration including updated trial data, new agents, and comparisons of oral antidiabetic agents with insulin.

    Article  PubMed  Google Scholar 

  6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

    Article  PubMed  CAS  Google Scholar 

  7. • Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2012;35(6):1364–79. This position statement is the first formal admonition of the patient-centered approach to diabetes management, issued jointly by the ADA and EASD.

    Article  PubMed  CAS  Google Scholar 

  8. • Oaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218–31. This clinical practice guideline is an appropriately up-to-date resource for a primary care audience.

    Article  Google Scholar 

  9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17–30.

    Article  PubMed  CAS  Google Scholar 

  10. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region: A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med. 1997;14:611–21.

    Google Scholar 

  11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.

    Article  PubMed  CAS  Google Scholar 

  12. ACCORD Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

    Google Scholar 

  13. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  PubMed  CAS  Google Scholar 

  14. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008;360(2):129–39.

    Article  PubMed  Google Scholar 

  15. American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35 suppl 1:S11–63.

    Google Scholar 

  16. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.

    Article  PubMed  Google Scholar 

  17. Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care. 2008;31(5):1046–50.

    Article  PubMed  Google Scholar 

  18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  PubMed  CAS  Google Scholar 

  19. • Perrault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243–51. The DPPOS emphasizes the importance of early intervention, at the stage of mild dysglycemia or pre-diabetes, with lifestyle modification and use of metformin.

    Article  Google Scholar 

  20. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors [Letter]. Arch Intern Med. 2009;169:1718–20.

    Article  PubMed  Google Scholar 

  21. Corsino L, Cox ME, Rowell J, Green JB. Present and prospective pharmacotherapy for the management of patients with type 2 diabetes. Clin Med Ther. 2009;1:1103–19.

    PubMed  CAS  Google Scholar 

  22. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1c levels: a systematic review and meta-analysis. Diabetes Care. 2010 August;33(8):1859–64.

  23. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.

    Article  PubMed  Google Scholar 

  24. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253–70.

    Article  CAS  Google Scholar 

  25. Lingvay I, Rhee C. and RaskinP. Noninsulin Pharmacological Therapies. In: Feinglos M, Bethel MA, editors. Type 2 diabetes mellitus: an evidence-based approach to practical management. Totowa: Humana; 2010. p. 151–67.

    Google Scholar 

  26. Lebovitz HE, Feinglos MN. Insulin resistance in patients with insulin independent diabetes mellitus: partial amelioration by the sulfonylurea glipizide. Adv Exp Med Biol. 1979;119:371–9.

    Article  PubMed  CAS  Google Scholar 

  27. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541–9.

    Article  PubMed  CAS  Google Scholar 

  28. Currie CL, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35(2):299–304.

    Article  PubMed  Google Scholar 

  29. Ruiter R, Visser LE, van Herk-Sukel MP. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012;35(1):119–24.

    Article  PubMed  CAS  Google Scholar 

  30. Glucophage® (metformin hydrochloride) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2009. Available at: http://packageinserts.bms.com/pi/pi_glucophage.pdf. Accessed on Mar 7, 2013.

  31. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012 Aug;13(12):1797–805.

  32. Actos® (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012. Available at: www.actos.com.

  33. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.

    Article  PubMed  CAS  Google Scholar 

  34. Erdmann E, Charbonnel B, Wilcox RG. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773–8.

    Article  PubMed  CAS  Google Scholar 

  35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.

    Article  PubMed  CAS  Google Scholar 

  36. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36.

    Article  PubMed  CAS  Google Scholar 

  37. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk for bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J. 2012;184(12):E675–83.

    Article  Google Scholar 

  38. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.

    Article  PubMed  Google Scholar 

  39. Takeda Pharmaceuticals North America. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HCL) tablets for type 2 diabetes mellitus (Letter to Health Care Providers), 2007. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150451.htm. Accessed December 21, 2012.

  40. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330–6.

    Article  PubMed  CAS  Google Scholar 

  41. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19 Suppl 2:789–830.

    PubMed  Google Scholar 

  42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  43. Riddle MC. Sulfonylureas differ in effects on ischemic preconditioning – is it time to retire glyburide? J Clin Endocrol Metab. 2003;88(2):528–30.

    Article  Google Scholar 

  44. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531–7.

    Article  PubMed  CAS  Google Scholar 

  45. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD004654.

  46. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  PubMed  CAS  Google Scholar 

  47. Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety. 2010;2:7–19.

    PubMed  CAS  Google Scholar 

  48. Januvia® [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2010. Available at: http://www.januvia.com/sitagliptin/januvia/consumer/prescribing-information-for-januvia/index.jsp. Accessed on Mar 7, 2013.

  49. Onglyza® [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2009. Available at: packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed on Mar 7, 2013.

  50. Tradjenta® [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009. Available at: www.tradjenta.com/prescribing-information. Accessed on Mar 7, 2013.

  51. Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet) - acute pancreatitis. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm. Accessed Jan 6, 2013.

  52. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57–64.

    Article  PubMed  CAS  Google Scholar 

  53. Wani JH, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin. 2008;26(4):639–48.

    Article  PubMed  Google Scholar 

  54. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension. 2009;54:516–52.

    Article  PubMed  CAS  Google Scholar 

  55. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–10.

    Article  PubMed  CAS  Google Scholar 

  56. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011;123(6):189–201.

    Article  PubMed  Google Scholar 

  57. Buse JB, Nauck MA, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized open-label study. Lancet. 2012;380:1–8.

    Article  Google Scholar 

  58. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81.

    Article  PubMed  CAS  Google Scholar 

  59. Buse JB, Nielsen LL, Guan X, Guan X, Bowlus CL, Holcombe JH, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label uncontrolled extension of three double blind, placebo-controlled trials. Clin Ther. 2007;29(1):139–53.

    Article  PubMed  CAS  Google Scholar 

  60. Klonoff DC, Nielsen LL, Guan X, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–86.

    PubMed  CAS  Google Scholar 

  61. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11 Suppl 3:26–34.

    Article  PubMed  CAS  Google Scholar 

  62. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–60.

    Article  PubMed  CAS  Google Scholar 

  63. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–8.

    Article  PubMed  CAS  Google Scholar 

  64. Pratley RE, Barnett A, Feinglos M, Harman-Boehm I, Nauck MA, Ovalle F. Efficacy and Safety of Once-Weekly (QW) Albiglutide vs. Once-Daily (QD) Liraglutide in Type 2 Diabetes (T2D) Inadequately Controlled on Oral Agents: Harmony 7 Trial. Diabetes. 2012;61 suppl 1:A240.

    Google Scholar 

  65. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271–84.

    Article  PubMed  CAS  Google Scholar 

  66. Byetta® (exenatide) injection [Prescribing Information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011. Available at: www.byetta.com/pi. Accessed on Mar 7, 2013.

  67. Victoza® (liraglutide [rDNA origin] injection), solution for subcutaneous use. Princeton, NJ: Novo-Nordisk Inc.; 2010. Available at: www.victoza.com.

  68. BYDUREON® (exenatide extended-release for injectable suspension) [Prescribing Information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012. Available at: www.BYDUREON.com/pi.

  69. Food and Drug Administration. Byetta (exenatide) – renal failure. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm. Accessed Jan 6, 2013.

  70. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–46.

    Article  PubMed  CAS  Google Scholar 

  71. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–30.

    Article  PubMed  CAS  Google Scholar 

  72. • Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. The ORIGIN trial showed no additional benefit on long-term outcomes with the early use of basal insulin as compared to other non-insulin medications.

  73. Diamant M, Van Gall L, Stranks S, Northrup J, Cao D, Taylor K. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–43.

    Article  PubMed  CAS  Google Scholar 

  74. Riddle MC. The transition from oral agents to combination insulin/oral therapy. In: Feinglos M, Bethel MA, editors. Type 2 diabetes mellitus: an evidence-based approach to practical management. Totowa: Humana. p. 169–81.

  75. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–5.

    Article  PubMed  CAS  Google Scholar 

  76. Boldo A, Comi RJ. Clinical experience with U500 insulin: risks and benefits. Endocr Pract. 2012;18(1):56–61.

    Article  PubMed  Google Scholar 

  77. De la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496–501.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Mary Elizabeth Cox declares that she has no conflict of interest.

Mark N. Feinglos has been a consultant for Eli Lilly, Pfizer, and GlaxoSmithKline. He has also received grant support from Amylin, AstraZeneca, Bristol-Meyers Squibb, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Novo Nordisk, Proctor & Gamble, Prodigy Diabetes Care, Sanofi-Aventis, and Tethys. Mark N. Feinglos declares that he has no conflict of interest.

Author information

Authors and Affiliations

  1. Medical Clinic of North Texas, 909 9th Ave, Ste 300, Fort Worth, TX, 76104, USA

    Mary Elizabeth Cox

  2. Duke University Medical Center, Box 3921, DUMC, Durham, NC, 27710, USA

    Mark N. Feinglos

Authors
  1. Mary Elizabeth Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark N. Feinglos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Elizabeth Cox.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cox, M.E., Feinglos, M.N. Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes. Curr Diab Rep 13, 319–328 (2013). https://doi.org/10.1007/s11892-013-0374-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-013-0374-z

Keywords

Search

Navigation